LTM 3Q18 Revenue $10.1 billion, +24% YoY, Core EBITDA margin 13.7% Core EBITDA of $409m in 3Q18, +40% YoY; $1,379m LTM 3Q18 (45% YoY) LTM 3Q18 Core EPS THB 4.49, +65% post 11.1% dilution from
% Portion of the Companies’ shareholders (272,672) (166,308) 64% (358,157) (621,089) -42% Margin -14% -8% -24% -38% 2 Financial performance in 2019 Revenue from sales and services for the year 2019 is Baht
31, 2020 as follows: Company’s Performance (unit: THB million) 2020 2019 Difference Percentage Revenue from Media-advertising 20.99 - 20.99 100.00 Revenue from organizing concerts - - - - Sale income
be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the
cycle. On the journey to achieve this, IVL is committed to: Cost transformation via the Olympus program, leading to $350M run-rate savings by 2023 Asset full potential with strong revenue and margin
committed to: Cost transformation via the Olympus program, leading to $350M run-rate savings by 2023 Asset full potential with strong revenue and margin growth across PET, IOD and Fibers through
% Dividend income - - - 15,000 35,000 -57% Gain on disposal of assets 308,107 - 100% 663 - 100% Other income 27,987 34,987 -19% 9,226 9,890 -7% Total Revenues 2,398,510 2,509,827 -4% 1,666,564 1,712,604 -3
were the main products of Company and its old subsidiaries. 1.2 Other income Other income consists of interest income, gain from asset sales and revenue from scrap sales. For the period of three months
Company and its old subsidiaries. 1.2 Other income Other income consists of interest income, gain from asset sales and revenue from scrap sales. For the period of three months ended 30th June 2020, the
summarized as follows: Consolidated FS Quarter 1/2019 Quarter 1/2020 Change MB. % MB. % MB. % Revenue from contracts with customers 1,943.6 70.9% 1,714.0 64.3% -229.6 -11.8% Interest income from loans from the